Brought to you by 
Series C lands $83mm for uBiome
25 Sep 2018
Executive Summary
Microbial genomics firm uBiome Inc. raised $83mm in its Series C financing led by OS Fund, which was joined by investors including 8VC, Y Combinator, and Dentsu Ventures. The six-year-old firm will use the proceeds for portfolio development, to expand into drug R&D using existing patent assets and research collaborations rather than data sales, to continue commercializing its SmartGut, SmartJane, Explorer diagnostics, and to commence commercialization of biopharma molecules and live biotherapeutics. UBiome concurrently announced that former Novartis CEO Joseph Jimenez will join the board.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C lands $83mm for uBiome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice